secwatch.observer — SEC 8-K summary
======================================

Issuer:     WINDTREE THERAPEUTICS INC /DE/ (WINT)
CIK:        0000946486
Form:       8-K
Filed at:   2024-12-04T23:59:59+00:00
Accession:  0001437749-24-036647
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Windtree engages New Growth Advisors to explore strategic options for cardiovascular portfolio
--------------------------------------------------------------------------------

- Engaged New Growth Advisors to lead out-licensing or asset sale process for istaroxime and oral SERCA2a activators.
- Company cites positive Phase 2b SEISMiC study in early cardiogenic shock as catalyst for potential non-dilutive partnership.
- Existing Lee's Pharmaceuticals deal offers up to $138M in milestones plus low double-digit royalties for Greater China.
- NGA has advised on transactions with aggregate value approaching $400M from 2023 through 2024.
- Proceeds from any deal would support advancement of Windtree's novel preclinical oncology platform.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/946486/000143774924036647/0001437749-24-036647-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/946486/000143774924036647/wint20241202_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-24-036647

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer